Department of Orthopaedics, Mianyang Central Hospital, Mianyang, China.
Department of Orthopaedics, PLA General Hospital, Beijing, China.
Orthop Surg. 2023 Jan;15(1):162-168. doi: 10.1111/os.13563. Epub 2022 Nov 20.
Survival and reconstruction in osteosarcoma is quite challenging. The study aimed to investigate the prognosis in patients treated with neoadjuvant chemotherapy and determine the clinical outcomes of expandable endoprosthesis reconstruction in children.
From January 2009 to December 2014, we retrospectively analyzed 29 skeletally immature children (mean age, 10.5 years; range, 6-15 years) with osteosarcoma around the knee. Of the 29 patients who underwent neoadjuvant chemotherapy and limb salvage surgery, an expandable prosthesis was implanted for reconstruction. No patients were missed during follow-up. The evaluation index involved follow-up time, complication, functional results, and lengthening procedures. The survivorship and recurrence were assessed by GraphPad Software, and the function was evaluated by the Musculoskeletal Tumor Society (MSTS) scoring system.
A mean follow-up time was 8.9 years (range, 6-12 years), and the overall 5-year survival was 89.1% based on Kaplan-Meier analysis. Three patients suffered a relapse and one underwent amputation. Lung metastasis developed in one patient. At 6 months after the operation, patients had a mean MSTS score of 27 points (range, 24-29). Two patients underwent revision surgery, one for implant infection and one for aseptic loosening. Prognosis is correlated with alkaline phosphatase change after treatment.
Chemotherapy scheme and limb salvage can achieve high survival rates. This expandable prosthesis was associated with good function and low complication rates. The character of expandability could be a method to overcome discrepancies in the growth period.
骨肉瘤的生存和重建极具挑战性。本研究旨在探讨新辅助化疗患者的预后,并确定儿童可膨胀假体重建的临床结果。
2009 年 1 月至 2014 年 12 月,我们回顾性分析了 29 例膝关节周围的未成年骨肉瘤患者(平均年龄 10.5 岁,范围 6-15 岁)。29 例患者均接受新辅助化疗和保肢手术,其中 21 例采用可膨胀假体进行重建。所有患者均获得随访,随访时间为 6-12 年,平均 8.9 年。随访期间评估指标包括:随访时间、并发症、功能结果和延长程序。采用 GraphPad 软件评估生存率和复发率,采用肌肉骨骼肿瘤学会(MSTS)评分系统评估功能。
平均随访时间为 8.9 年(范围 6-12 年),Kaplan-Meier 分析显示总体 5 年生存率为 89.1%。3 例患者复发,1 例患者截肢。1 例患者发生肺转移。术后 6 个月,患者的平均 MSTS 评分为 27 分(范围 24-29)。2 例患者行翻修手术,1 例因假体感染,1 例因无菌性松动。预后与治疗后碱性磷酸酶的变化相关。
化疗方案和保肢治疗可以获得较高的生存率。这种可膨胀假体具有良好的功能和较低的并发症发生率。可膨胀性的特点可能是克服生长期差异的一种方法。